Comparison Chart Outlook Therapeutics, Inc.
Stocks
OTLK
US69012T3059
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
04:00:00 29/10/2026 HKT
|
5-day change | 1st Jan Change | ||
| 0.5449 USD | +2.85% |
|
-2.92% | -65.51% |
| 10-12 | Certain Common Stock of Outlook Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 12-OCT-2026. | CI |
| 10-09 | Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| OUTLOOK THERAPEUTICS, INC. | Other Biotechnology & Medical Research | +2.85% | -2.92% | -65.51% | -59.03% | -98.70% | 129M |  |  | |
- Stock Market
- Stocks
- OTLK Stock
- Charts Outlook Therapeutics, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
